Pancreatic Neuroendocrine Tumors in MEN1 Disease: A Monocentrice Longitudinal and Prognostic Study Abstract #1907

Introduction: In MEN1+ patients (MEN+), pNETs are considered to be high risk for multiple, malignant and aggressive tumors.
Aim(s): To describe clinical and prognostic pNET in MEN+
Materials and methods: To compare pNET in MEN+ with cG/hG-adjusted pNET in MEN-
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: md Sabrina Chiloiro
Keywords: pNETs, MEN, prognosis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#3048 Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors
Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: PhD Giovanni Schinzari
#3069 Functioning Pancreatic Neuroendocrine Tumors (F-pNETs): The Experience of a Tertiary Care Center of Pancreatic Surgery
Introduction: Surgery represents the optimal treatment of F-pNETs, especially if performed in high volume centers of pancreatic surgery.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Chiara Nessi
Authors: Nessi C, Lenzi S, Landoni L, Bianchi B, ...
#2957 New Evidence of Emerging Nodal Metastasis in Staging System after Surgical pNET Resection as Predictive Factor for Recurrence. Result from Monocentric Retrospective Series
Introduction: New evidence is emerging of the role of pNETs lymphatic metastasis in terms of Oncological Outcomes. A specific staging classification is not actually available.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Laura Mastrangelo
#2986 Characterization of 142 Human Pancreatic Neuroendocrine Tumors: ATRX and DAXX Correlation with Clinical-Pathological Data
Introduction: Pancreatic neuroendocrine tumors (PNETs) are rare and heterogeneous neoplasms with a 10-year survival rate less than 30%. Up to 43% of them are driven by inactivating mutations in ATRX or DAXX. These are important players at chromatin remodeling, that when mutated prone cancer cells to initiate the alternative lengthening of telomeres (ALT). ALT phenotype correlates with in situ loss of expression of the proteins ATRX or DAXX and can be corroborated by telomere-FISH.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: DVM Tiago B Gaspar
#2733 Pancreatic Metastases Originating from Intestinal Neuroendocrine Tumours
Introduction: Pancreatic metastases are rare, accounting for 1 to 2% of pancreatic tumours. Data on pancreatic metastases of intestinal NETs are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Anja Rinke